158 related articles for article (PubMed ID: 32258980)
21. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement.
Dibba P; Ludwig E; Calo D; Gerdes H; Markowitz A; Shike M; Schattner M; Mendelsohn R
Surg Endosc; 2021 Jun; 35(6):2976-2980. PubMed ID: 32583069
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary report on prospective, multicenter, open research of selective surgery after expandable stent combined with neoadjuvant chemotherapy in the treatment of obstructive left hemicolon cancer].
Han J; Wang Z; Dai Y; Li X; Qian Q; Wang G; Wei G; Zeng W; Ma L; Zhao B; Wang Y; Yang K; Ding Z; Hu X
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1233-1239. PubMed ID: 30506533
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001).
Hwang WY; Chang SJ; Kim HS; Kim NK; Kim TH; Kim Y; Kong TW; Lee EJ; Park SJ; Shim SH; Son JH; Suh DH; Yang EJ
BMC Cancer; 2022 Jun; 22(1):603. PubMed ID: 35655188
[TBL] [Abstract][Full Text] [Related]
25. [Short-term outcomes and prognosis of palliative surgery for malignant bowel obstruction caused by peritoneal metastasis of colorectal cancer].
Chen PJ; Wang L; Chen N; Lu XY; Wang HS; He X; Wang Z; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Nov; 22(11):1051-1057. PubMed ID: 31770836
[No Abstract] [Full Text] [Related]
26. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
Hapani S; Chu D; Wu S
Lancet Oncol; 2009 Jun; 10(6):559-68. PubMed ID: 19482548
[TBL] [Abstract][Full Text] [Related]
27. Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents.
Pacheco-Barcia V; Mondéjar R; Martínez-Sáez O; Longo F; Moreno JA; Rogado J; Donnay O; Santander C; Carrato A; Colomer R
Clin Colorectal Cancer; 2019 Sep; 18(3):e287-e293. PubMed ID: 31262698
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
[TBL] [Abstract][Full Text] [Related]
29. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
30. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
Abbrederis K; Kremer M; Schuhmacher C
Chirurg; 2008 Apr; 79(4):351-5. PubMed ID: 17453167
[TBL] [Abstract][Full Text] [Related]
31. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
32. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of short-term efficacy of perioperative fecal microbiota transplantation combined with nutritional support in patients with radiation-induced enteritis complicated by intestinal obstruction].
Cui JQ; Tian HL; Wang XJ; Wang L; Liu YK; Ye C; Ding LF; Li N; Chen QY
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Oct; 26(10):955-962. PubMed ID: 37849266
[No Abstract] [Full Text] [Related]
34. Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality.
Giakoustidis A; Neofytou K; Khan A; Mudan S
Hepat Oncol; 2014 Oct; 1(4):363-375. PubMed ID: 30190972
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival.
Storandt MH; Tran NH; Ehret CJ; Hanna M; Jochum J; Moynagh MR; Jatoi A
World J Surg Oncol; 2023 Jun; 21(1):177. PubMed ID: 37291587
[TBL] [Abstract][Full Text] [Related]
36. Gastrointestinal Perforation With an Intraluminal Stent and Bevacizumab use in Advanced Metastatic Colorectal Cancer.
Akeel N; Toonsi WA
Cureus; 2021 Jan; 13(1):e12831. PubMed ID: 33628692
[TBL] [Abstract][Full Text] [Related]
37. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.
Hagiwara S; Komeda Y; Nishida N; Yoshida A; Kudo M
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1721. PubMed ID: 36224043
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer.
Kim S; Shin JK; Park Y; Huh JW; Kim HC; Yun SH; Lee WY; Cho YB
Front Oncol; 2022; 12():1018458. PubMed ID: 36353568
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Gruenberger B; Tamandl D; Schueller J; Scheithauer W; Zielinski C; Herbst F; Gruenberger T
J Clin Oncol; 2008 Apr; 26(11):1830-5. PubMed ID: 18398148
[TBL] [Abstract][Full Text] [Related]
40. Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial.
Xiao J; Chen Z; Li W; Yang Z; Huang Y; Zheng J; Deng Y; Wang L; Ren D; Peng J; Lan P; Wang J
Cancer Chemother Pharmacol; 2015 Jul; 76(1):21-7. PubMed ID: 25952796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
